Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

5-25歲近期發病第3期第1型糖尿病患者中，抗胸腺細胞球蛋白（antithymocyte globulin）最低有效低劑量（MELD-ATG）的研究：第二期、多中心、雙盲、隨機、安慰劑對照、劑量調整試驗